European Heart Journal Advance Access originally published online on August 8, 2005
European Heart Journal 2005 26(22):2457-2462; doi:10.1093/eurheartj/ehi438
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Gene-specific modifying effects of pro-LVH polymorphisms involving the renin–angiotensin–aldosterone system among 389 unrelated patients with hypertrophic cardiomyopathy
1Mayo Medical School, Mayo Clinic College of Medicine, Rochester, MN, USA
2Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, Rochester, MN, USA
3Department of Paediatric and Adolescent Medicine, Mayo Clinic College of Medicine, Rochester, MN, USA
4Department of Internal Medicine, Division of Cardiovascular Medicine, Mayo Clinic College of Medicine, Rochester, MN, USA
5Department of Paediatric and Adolescent Medicine, Division of Paediatric Cardiology, Mayo Clinic College of Medicine, Rochester, MN, USA
Received 12 January 2005; revised 16 June 2005; accepted 7 July 2005; online publish-ahead-of-print 8 August 2005.
* Corresponding author: Sudden Death Genomics Laboratory, 501 Guggenheim, 200 First Street SW, Rochester, MN 55905, USA. E-mail address: ackerman.michael@mayo.edu
Aims The purpose of this study was to determine whether the deletion/insertion (D/I) polymorphism in the ACE-encoded angiotensin-converting enzyme or the pooled gene effect of five renin–angiotensin–aldosterone system (RAAS) polymorphisms were disease modifiers in a large cohort of unrelated patients with genotyped hypertrophic cardiomyopathy (HCM).
Methods and results Five different RAAS polymorphism genotypes were established by PCR amplification of the surrounding polymorphic regions of genomic DNA in a cohort of 389 unrelated patients comprehensively genotyped for HCM-causing mutations in eight sarcomeric/myofilament genes. Patient clinical data were archived in a database blinded both to the primary myofilament defect and the polymorphism genotype. Each patient was assessed with respect to ACE genotype as well as composite pro-left ventricular hypertrophy (LVH) RAAS polymorphism score (0–5). Overall, no clinical parameter correlated independently with ACE genotype. Subset analysis of the two most common genetic subtypes of HCM, MYBPC3 (myosin binding protein C) and MYH7 (beta myosin heavy chain), demonstrated a significant pro-LVH effect of DD-ACE only in patients with MYBPC3-HCM. In MYBPC3-HCM, left ventricular wall thickness was greater in patients with DD genotype (25.8±5 mm) compared with DI (21.8±4) or II genotype (20.8±5, P=0.01). Moreover, extreme hypertrophy (>30 mm) was only seen in MYBPC3-HCM patients who also hosted DD-ACE. An effect of RAAS pro-LVH score was evident only in the subgroup of patients with no previously identified myofilament mutation.
Conclusion This study demonstrates that RAAS genotypes may modify the clinical phenotype of HCM in a disease gene-specific fashion rather than indiscriminately.
Key Words: Hypertrophic cardiomyopathy • ACE polymorphism • Genetic testing • Left ventricular hypertrophy • Renin–angiotensin–aldosterone system
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P. Richard, E. Villard, P. Charron, and R. Isnard The Genetic Bases of Cardiomyopathies J. Am. Coll. Cardiol., October 27, 2006; 48(9_Suppl_A): A79 - A89. [Abstract] [Full Text] [PDF]
|
|